Healthcare Industry News: Mylan
News Release - July 21, 2008
Daniel E. Crookshank Joins Mylan as Vice President - Investor RelationsPITTSBURGH, July 21 (HSMN NewsFeed) -- Mylan Inc. (NYSE: MYL ) announced today the appointment of Daniel E. Crookshank as vice president - Investor Relations and as a member of the company's senior leadership team. Reporting to Chief Financial Officer Edward J. Borkowski, Crookshank is responsible for all investment community communication as well as for the development and direction of activities that proactively promote Mylan to the investment community.
"Dan has a well-deserved reputation as an outstanding, senior investor relations professional," said Mylan Vice Chairman and CEO Robert J. Coury. "His extensive international experience - together with his comprehensive knowledge of finance and solid accounting background - will serve the company well going forward. We're excited to have an individual with Dan's talents joining our Mylan team."
Crookshank served most recently as vice president - Investor Relations for Rockwell Collins, a global manufacturer of communications and aviation electronics solutions for commercial and military customers worldwide. During his 18-year career with Rockwell Collins and Rockwell International, he served in a number of increasingly responsible positions within Finance. Crookshank also completed accounting assignments with National Steel Corporation and H.J. Heinz Corporation. He began his business career with the public accounting firm Deloitte, Haskins & Sells, now Deloitte & Touche.
Crookshank earned a bachelor's degree in business administration from Robert Morris University and an MBA from the Katz Graduate School of Business at the University of Pittsburgh.
Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer